Brief: Bristol Myers Squibb Presents Positive Results From Phase 3 Scout-Hcm Trial Demonstrating Efficacy And Safety Of Camzyos (Mavacamten) In Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy (Ohcm)

Bristol-Myers Squibb Co

29/03/2026 16:47

March 29 (Reuters) - Bristol-Myers Squibb Co BMY.N:

BRISTOL MYERS SQUIBB PRESENTS POSITIVE RESULTS FROM PHASE 3 SCOUT-HCM TRIAL DEMONSTRATING EFFICACY AND SAFETY OF CAMZYOS (MAVACAMTEN) IN ADOLESCENTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)

BRISTOL-MYERS SQUIBB CO - SCOUT-HCM TRIAL MEETS PRIMARY ENDPOINT WITH SIGNIFICANT LVOT GRADIENT REDUCTION AT WEEK 28

BRISTOL-MYERS SQUIBB CO: RESULTS DEMONSTRATE POTENTIAL FOR CAMZYOS TO BE FIRST TARGETED PHARMACOLOGICAL THERAPY FOR TREATMENT OF OHCM IN ADOLESCENTS

BRISTOL-MYERS SQUIBB CO: SAFETY PROFILE OF CAMZYOS IN ADOLESCENTS WAS SIMILAR TO ESTABLISHED PROFILE IN ADULTS

Source text: ID:nBw4Zw9L8a

Further company coverage: BMY.N

 ((Reuters.Briefs@thomsonreuters.com;))